fluorodeoxyglucose f18 has been researched along with melphalan in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoekstra, HJ; Nieweg, OE; Oldhoff, J; Paans, AM; Pruim, J; Schraffordt Koops, H; Vaalburg, W | 1 |
| Hoekstra, HJ; Koops, HS; Molenaar, WM; Nieweg, OE; Paans, AM; Pruim, J; Vaalburg, W; van Ginkel, RJ; Willemsen, AT | 1 |
| Alavi, A; Bénard, F; Fraker, D; Jimenez-Hoyuela, J; Lampreave, JL | 1 |
| Au, WY; Kwong, YL; Leung, G; Liang, R; Ma, SK; Ooi, GC; Shek, TW | 1 |
| Alavi, A; Fraker, DL; Mercier, GA | 1 |
| Ansén, S; Bischoff, S; Bohlen, H; Diehl, V; Dietlein, M; Re, D; Scheidhauer, K; Schicha, H; Tesch, H; Weihrauch, MR; Wolf, J | 1 |
| Becherer, A; Dudczak, R; Greinix, HT; Jaeger, U; Kalhs, P; Karanikas, G; Kletter, K; Mitterbauer, M; Pötzi, C; Raderer, M | 1 |
| Hill, AD; Ryan, ER; Skehan, SJ | 1 |
| Alinari, L; Baccarani, M; Derenzini, E; Fanti, S; Gandolfi, L; Musuraca, G; Stefoni, V; Tani, M; Venturini, F; Zinzani, PL | 1 |
| Kuruvilla, J | 1 |
| Qiao, W; Wang, C; Wang, T; Xing, Y; Zhao, J | 1 |
| Andreou, D; Boldt, H; Jobke, B; Pink, D; Reichardt, P; Schuler, M; Tunn, PU; Werner, M | 1 |
| Arranz, R; Bargay, J; Bello, JL; Caballero, MD; Conde, E; Coronado, M; González-Barca, E; Grande, C; Hernández, MT; Marín-Niebla, A; Martín, A; Montes-Moreno, S; Panizo, C; Pardal, E; Pérez-Ceballos, E | 1 |
| Butcher, B; Chong, G; Cull, G; Fay, K; Filshie, R; Gandhi, MK; Gill, D; Grigg, A; Hahn, U; Hertzberg, M; Hicks, RJ; Ho, SJ; Hofman, MS; Johnston, A; Kannourakis, G; Lewis, ID; Milliken, S; Renwick, W; Seymour, JF; Taper, J; Trotman, J; Warburton, P; Watson, AM; Wirth, A | 1 |
1 review(s) available for fluorodeoxyglucose f18 and melphalan
| Article | Year |
|---|---|
Standard therapy of advanced Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Mechlorethamine; Melphalan; Methylprednisolone; Positron-Emission Tomography; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2009 |
5 trial(s) available for fluorodeoxyglucose f18 and melphalan
| Article | Year |
|---|---|
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Vincristine | 2008 |
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Predictive Value of Tests; Prednisolone; Prednisone; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Teniposide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2010 |
Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Extremities; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prednisone; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Positron-Emission Tomography; Prednisone; Retreatment; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2017 |
8 other study(ies) available for fluorodeoxyglucose f18 and melphalan
| Article | Year |
|---|---|
Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma.
Topics: Chemotherapy, Cancer, Regional Perfusion; Contrast Media; Deoxyglucose; Fluorodeoxyglucose F18; Humans; Interferon-gamma; Leg; Liposarcoma; Male; Melphalan; Middle Aged; Soft Tissue Neoplasms; Tomography, Emission-Computed; Tumor Necrosis Factor-alpha | 1994 |
FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxyglucose; Extremities; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Hyperthermia, Induced; Interferon-gamma; Male; Melphalan; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Tomography, Emission-Computed; Tumor Necrosis Factor-alpha | 1996 |
PET evaluation of therapeutic limb perfusion in Merkel's cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma, Merkel Cell; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorodeoxyglucose F18; Humans; Leg; Melphalan; Radiopharmaceuticals; Recurrence; Skin Neoplasms; Tomography, Emission-Computed; Tumor Necrosis Factor-alpha | 1998 |
Myeloblastoma (chloroma) in leukemia: case 2. Meningeal granulocytic sarcoma (chloroma) in essential thrombocythemia.
Topics: Antineoplastic Agents, Alkylating; Female; Fluorodeoxyglucose F18; Humans; Leukemia, Myeloid; Melphalan; Meningeal Neoplasms; Middle Aged; Neoplasms, Second Primary; Thrombocytosis; Tomography, Emission-Computed | 2000 |
FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Drug Therapy, Combination; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Likelihood Functions; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tumor Necrosis Factor-alpha; Whole-Body Counting | 2001 |
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease-Free Survival; Doxorubicin; Etoposide; False Negative Reactions; False Positive Reactions; Fibrosis; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Life Tables; Mediastinal Neoplasms; Melphalan; Neoplasm Recurrence, Local; Predictive Value of Tests; Prednisone; Procarbazine; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Tomography, Emission-Computed; Transplantation, Autologous; Vinblastine; Vincristine | 2001 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prognosis; Radiopharmaceuticals; Survival Analysis; Survival Rate; Tomography, Emission-Computed; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2002 |
FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Fluorodeoxyglucose F18; Infusions, Intra-Arterial; Lymphatic Metastasis; Melanoma; Melphalan; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2006 |